A Practical Guide to Writing Risk Management Plans (RMPs)

Understand RMPs relationship to safety reviews; PBRERs/DSURs; licence submissions (CTD) and their maintenance

28 Jan 2019

& 3 Jul 2019

GBP 699
EUR 979
USD 1,090

Book now

Course Overview

The pharmacovigilance legislation of 2012 requires companies to provide Risk Management Plans (RMPs) and assessments for all new products, whether generic products or new chemical entities. If these are not done correctly this can delay both licensure and sales and damage the company’s ability to maximise its products. Maintenance of RMPs is also an important aspect of maintaining compliance.

Topics to be covered will include:

  • An Introduction to ICH & EU RMPs – Production & Maintenance
  • Documentation to be Supplied to Regulatory Authorities – the process for RMPs
  • The EU Templates & their Completion – Generic and Innovator Products
  • RMPs in other Countries
  • Practical – Completion of Sections I – III
  • Practical – Completion of Sections IV – VI
  • Practical – Completion of Annexes

Please note that we are also running:

Book together and save

This meeting runs back-to-back with Producing and Maintaining the Pharmacovigilance System Master File (PSMF) on 5 July 2018 and also Risk Evaluation and Mitigation Strategies (REMS) on 6 July 2018. There is a further £100/€140 discount off each course when booked together.

To find out more please call Customer Services on +44 (0)20 7749 4730 or e-mail info@management-forum.co.uk

Who should attend

This course will be relevant for anyone requiring a comprehensive overview of the pharmacovigilance function and duties and may be of particular interest to those who are responsible in pharmacovigilance for any safety assessments and writing such plans including any medical directors who approve such plans. those who work with pharmacovigilance, e.g. regulatory affairs, clinical, sales and marketing, legal, commercial and quality and EU QP PVs that must sign off such documents.


09.00 Registration and Coffee

09.30 Meeting begins

An Introduction to EU RMPs – Production & Maintenance

  • ICH E2E – Risk Management Plans
  • EU Module V – Risk Management Plans
  • Production of the EU RMP
  • Maintenance of the RMP (Safety Reviews; PSURs/DSURs)

Documentation to be Supplied to Regulatory Authorities – the process for RMPs

  • Generic RMPs
  • RMPs for Innovator products
  • Additional documents to supply to the Regulators
  • Safety reporting Timelines for RMPs
  • Japan and the USA and RMPs

The EU Templates & their Completion – Generic and Innovator Products Including RMPs in other Countries

  • The EU Generic template
  • The EU Template for innovator products
  • The RMP Template in Japan

Practical – Completion of Sections I – III

  • Section I – Information sources and completion
  • Section II – Common aspects for Risk appraisal from Clinical Studies
  • Section III – The Pharmacovigilance Plan

Practical – Completion of Sections IV – VI

  • Section IV – Post Authorisation Efficacy Studies
  • Section V – Risk Minimisation Activities
  • Section VI – Summary of the RMP

Practical – Completion of Annexes

  • Annex 1: Interface between RMP and Eudravigilance/EPITT
  • Annex 2: Summary of product characteristics (SmPC) and package leaflet.
  • Annex 3: Worldwide marketing authorisation status by country (including EEA)
  • Annex 4: Synopsis of on-going and completed clinical trial programme
  • Annex 5: Synopsis of on-going and completed pharmacoepidemiological study programme
  • Annex 6: Protocols for proposed and on-going studies
  • Annex 7: Specific adverse event follow-up forms
  • Annex 8: Protocols for proposed and on-going studies in RMP part IV
  • Annex 9: Synopsis of newly available study reports for RMP parts III-IV
  • Annex 10: Details of proposed additional risk minimisation activities (if applicable)
  • Annex 11: Mock up examples of the material provided to healthcare professionals and patients
  • Annex 12: Other supporting data (including referenced material)

17.00 Meeting ends


Graeme Ladds (28 Jan 2019)

Graeme Ladds, Director of PharSafer, has over 30 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

Book now

28 Jan 2019
28 Jan 2019 Cavendish Hotel, London GBP 699.00
EUR 979.00
USD 1,090.00
+ VAT @ 20.00%
Enrol now
3 Jul 2019
3 Jul 2019 Venue not yet confirmed
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • Alfa Wassermann S.p.A.
  • Alfrapharma Srl
  • Archigen Biotech Limited
  • Cmed
  • Colgate-Palmolive R&D
  • Creo Pharma Ltd
  • DBV Technologies
  • ELPEN Pharmaceutical Co Inc
  • Ewopharma International s.r.o
  • Ferrer Internacional, S.A.
  • Icon Clinical Research (UK) Limited
  • Iggea Ltd
  • Jacobsen Pharma & MedTech Advice A/S
  • Janssen Pharmaceutica NV
  • Janssen-Cilag Limited
  • JensonR+ Ltd
  • Kem Pharmaceuticals Limited
  • Kyowa Kirin Services Ltd
  • Mapi Life Sciences Canada Inc.
  • Mediplex Ltd
  • Norgine Ltd.
  • Real Regulatory Ltd
  • Recordati
  • Red Line Pharmacovigilance
  • Research and Markets
  • VAN Pharma Consult

I enjoyed Graemes real world examples. He addresses people with different knowledge abilities very well

Alice King, Regulatory Affairs Associate, Creo Pharma Ltd

Good course, would recommend it to others as well. Speakers well prepared and the presentation was good.

Gabor Varbiro, Medical Adviser, Wockhardt UK Ltd

Overall a well organized course providing relevant knowledge about preparing RMPs. The presentation was good and the presenter has a substantial experience in the field of PV.

Gabor Varbiro, Medical Adviser, Wockhardt UK Ltd

I have always found Management Forum courses to be of a high standard. They are my preferred teaching and training source for staff at Redline PV

Shirley-Ann Van Der Spuy, QPPV, Redline Pharmacovigilance Ltd

Good course, good topic. Practical details offered, experiences. The speaker is excellent with the topic and has great experience.

Jorge Ignacio Gonzalez Borroto, Pharmacovigilance Officer, Grupo Ferrer Internacional SA

Very useful and engaging

Lauren Tuitt, , ProductLife


Yusouf Bah, Drug Safety and Pharmacovigilance Manager, DBV Technologies